Sofosbuvir and ribavirin in adolescents 12‐17 years old with hepatitis C virus genotype 2 or 3 infection

Children with chronic hepatitis C virus infection have limited treatment options. We evaluated the all‐oral combination of sofosbuvir and ribavirin in adolescents aged 12‐17 with hepatitis C virus genotype 2 or 3 (ClinicalTrials.gov NCT02175758). Fifty‐two patients received sofosbuvir 400 mg once da...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hepatology (Baltimore, Md.) Md.), 2017-10, Vol.66 (4), p.1102-1110
Hauptverfasser:	Wirth, Stefan, Rosenthal, Philip, Gonzalez‐Peralta, Regino P., Jonas, Maureen M., Balistreri, William F., Lin, Chuan‐Hao, Hardikar, Winita, Kersey, Kathryn, Massetto, Benedetta, Kanwar, Bittoo, Brainard, Diana M., Shao, Jiang, Svarovskaia, Evguenia, Kirby, Brian, Arnon, Ronen, Murray, Karen F., Schwarz, Kathleen B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adolescents Antiviral Agents - pharmacokinetics Antiviral Agents - therapeutic use Antiviral drugs Child Children Chronic infection Cirrhosis Disease transmission Female Genotype & phenotype Headache Hepacivirus - genetics Hepatitis Hepatitis C Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology Hepatology Humans Infections Interferon Liver Liver cirrhosis Male Nausea Pharmacokinetics Ribavirin Ribavirin - pharmacokinetics Ribavirin - therapeutic use Sampling Sofosbuvir - pharmacokinetics Sofosbuvir - therapeutic use Sustained Virologic Response Teenagers
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!